LONDON, November 3, 2016 /PRNewswire/ --
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this 191-page report you will receive 113 tables, charts and graphs - all unavailable elsewhere.
The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Cystic Fibrosis market forecasts from 2016-2026
• Cystic Fibrosis submarket forecasts from 2016-2026 covering: - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - Protein Transcription Modulators - Pancreatic Enzyme Products (PEP) - Other therapies
To see a report overview please email Sara Peerun on [email protected]
• Individual drug revenue forecasts from 2016-2026 by pharmacological classes:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators: • Orkambi • Kalydeco • VX-661 + ivacaftor • Second corrector/VX-661/ivacaftor
- Protein Transcription Modulators • Pulmozyme • QR-010 • Translarna
- Pancreatic Enzyme Products (PEP) • Ceron
- Other therapies • Cayston • TOBI
• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market
• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026
• Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis
• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe
• Discussion on selected leading companies marketing and developing cystic fibrosis drugs: - Vertex Pharmaceuticals - Roche - AbbVie - Gilead Sciences - Novartis
Visiongain's study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.
Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1749/Global-Cystic-Fibrosis-Therapeutics-Market-2016-2026
List of Companies and Organisations:
AbbVie
Aradigm
Aurora Biosciences
Bayer
Celtaxsys
Chiesi
Chugai Pharmaceutical Co.
Concert Pharmaceuticals
Corbus Pharmaceuticals
Cyclacel Pharmaceuticals
Demegen
EmphyCorp
EryDel
FDA
Genentech
Genkyotex
Gilead
InDex Pharmaceutials
ManRos Therapeutics
NanoBio
NICE
NIH
Novartis
Novoteris
Ocean Therapeutics
OrPro Therapeutics
Polydex Pharmaceuticals
ProQR Therapeutics
Pulmatrix
Roche
Shire
Teva
The University of Iowa
The University of Wisconsin
The University of Wisconsin System
UCB
University of Maryland
Vectura
Vertex Pharmaceuticals
ViroChem Pharma
XOMA
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
Advertisement
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
Advertisement
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this 191-page report you will receive 113 tables, charts and graphs - all unavailable elsewhere.
The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Cystic Fibrosis market forecasts from 2016-2026
• Cystic Fibrosis submarket forecasts from 2016-2026 covering: - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - Protein Transcription Modulators - Pancreatic Enzyme Products (PEP) - Other therapies
To see a report overview please email Sara Peerun on [email protected]
• Individual drug revenue forecasts from 2016-2026 by pharmacological classes:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators: • Orkambi • Kalydeco • VX-661 + ivacaftor • Second corrector/VX-661/ivacaftor
- Protein Transcription Modulators • Pulmozyme • QR-010 • Translarna
- Pancreatic Enzyme Products (PEP) • Ceron
- Other therapies • Cayston • TOBI
• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market
• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026
• Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis
• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe
• Discussion on selected leading companies marketing and developing cystic fibrosis drugs: - Vertex Pharmaceuticals - Roche - AbbVie - Gilead Sciences - Novartis
Visiongain's study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.
Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1749/Global-Cystic-Fibrosis-Therapeutics-Market-2016-2026
List of Companies and Organisations:
AbbVie
Aradigm
Aurora Biosciences
Bayer
Celtaxsys
Chiesi
Chugai Pharmaceutical Co.
Concert Pharmaceuticals
Corbus Pharmaceuticals
Cyclacel Pharmaceuticals
Demegen
EmphyCorp
EryDel
FDA
Genentech
Genkyotex
Gilead
InDex Pharmaceutials
ManRos Therapeutics
NanoBio
NICE
NIH
Novartis
Novoteris
Ocean Therapeutics
OrPro Therapeutics
Polydex Pharmaceuticals
ProQR Therapeutics
Pulmatrix
Roche
Shire
Teva
The University of Iowa
The University of Wisconsin
The University of Wisconsin System
UCB
University of Maryland
Vectura
Vertex Pharmaceuticals
ViroChem Pharma
XOMA
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
